Clinical trial · Interventional
Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer
Exercise Training as a Novel Primary Therapy for Men With Localised Prostate Cancer: the PANTERA Trial (Prostate cAncer Novel ThERApy)
NCT02409212CI-TRIAL-00036830PANTERAcompletedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Study design: The study is a two arm randomised controlled trial (randomisation ratio 1:1) comparing an aerobic exercise training intervention to usual care plus exercise advice. The primary outcome is the feasibility of the intervention as novel primary therapy in men with localised prostate cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostate Cancer | Malignant Prostate Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Aerobic exercise training | Behavioral | — | UNRESOLVED |
| Placebo surveillance and written exercise guidelines | Behavioral | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Intervention
- description
- 12 months of aerobic exercise training with behaviour change support
- interventionNames
- Behavioral: Aerobic exercise training
- type
- PLACEBO_COMPARATOR
- label
- Comparison
- description
- Optimal active surveillance according to NICE guidelines and written exercise guidelines from Macmillan cancer
- interventionNames
- Behavioral: Placebo surveillance and written exercise guidelines
Primary outcomes (1)
- measure
- Feasibility as measured by rate of recruitment
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Male
Show eligibility criteria text
Inclusion Criteria: In accordance with NICE active surveillance guidelines, men: * Who have been evaluated using a combination of clinical, bio-chemical, imaging and/or biopsy, within the last 12 months * With histologically confirmed low or intermediate risk prostate cancer, Gleason score ≤7 (3+4, not 4+3) * With up to T2a clinical stage tumours * With pre-treatment PSA ≤20 ng/mL * Who are willing to participate in optimal active surveillance and provide written informed consent * With life expectancy of ≥10 years Exclusion Criteria: Men: * With unstable angina * With uncontrolled hypertension * With recent myocardial infarction (within the past 6 months) * With pacemakers * Already undertaking regular physical activity (greater than 90 minutes of moderate intensity exercise, per week) will be excluded * With any other physical or mental limitation preventing participation in trial assessments * Participating in other clinical trials which might bias the evaluation of the primary objectives of the present study
References
Publications (0)
Data not yet available
No reference posted for this study.